Following the release of the top-line results of the Ph2 trial for Phelan-McDermid syndrome, the market capitalisation at the end of December 2023 was $3.18B, an increase of $2.20B (215%) over the past 12 months.
The MC increase is in part explained by the issue of 700,000 new shares, which had little impact on the upward movement in price over the month.
Following the release of the top-line results of the Ph2 trial...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |